REPAIR THERAPEUTICS INC. : Regulation FD Disclosure, financial statements and supporting documents (form 8-K)

Article 7.01 Regulation FD Disclosure.

At January 7, 2022, Therapeutic repair (the “Company”) issued a press release providing a business update and outlining planned next steps, including planned data readings from the Company’s clinical trial expansion cohorts on RP-3500, the planned launch of a phase 2 TRESR monotherapy trial RP-3500 in the first quarter of 2022, the planned launch of a pediatric phase 1 module of the TRESR trial of RP-3500 monotherapy in children during the first quarter of 2022 and the planned launch of studies enabling IND in the Company’s Polq¸ inhibitor program in the first half of 2022. A copy of the press release is attached in as part 99.1.

As stated previously in december 2021, the Company initiated its Phase 1 clinical trial of RP-6306 in combination with gemcitabine for the treatment of advanced molecularly selected solid tumors. In addition, the Company reaffirms its previous direction of reporting early clinical data for RP-6306 in the second half of 2022.

The management of the company will present at the 40th edition of the next edition JP Morgan Healthcare Conference to Wednesday, January 13, 2022 at 3:45 p.m. ET. The presentation will be webcast live and will be available by clicking on a link available in the Investors section of the Company’s website at

At January 10, 2022, the Company plans to issue an updated corporate presentation dated January 2022 providing a general corporate update as well as the aforementioned updates regarding its planned next steps for 2022. The corporate presentation will be available in the “News and Events” section of the Company’s website, located at news-and-events / presentations. The Company intends to use this presentation at the 40th JP Morgan Healthcare Conference
from January 10, 2022 as well as in future meetings with analysts, investors and others from time to time.

The information in this Item 7.01, including Exhibit 99.1, is provided and will not be considered “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the obligations of this section, and such information will not be deemed to be incorporated either. by reference in any filing under the Securities Act or the Exchange Act, unless expressly stated by specific reference in such filing.

Forward-looking statements

This current report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this current report on Form 8-K other than statements of historical fact could be considered as forward-looking, including, but not limited to, statements regarding clinical development plans and the business strategy of the Company. Company, including statements regarding the Company’s plans and timelines for the development of RP-3500 and RP-6306 including plans and timelines for continued development in any phase of clinical trial expansion as well as expected data reading dates; the potential therapeutic effects and the expected clinical benefits of RP-3500 and RP-6306, as monotherapy and in combination; and whether the preclinical or early clinical results of
RP-3500, RP-6306 and the Company’s Polq¸ inhibitor program will predict future clinical trials. Words such as “plan”, “expect”, “will”, “must”, “plan”, “continue”, “expand”, “move forward”, “believe”, “guide”, “target” , “May,” “remain”, “project”, “prospect”, “intend”, “estimate”, “could”, “should” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. The forward-looking statements contained herein speak only as of the date of this current report on Form 8-K, and the Company does not undertake to update these forward-looking statements. Forward-looking statements are based on management’s current beliefs and assumptions which are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement due to various factors, including, without limitation, the impacts of the COVID-19 pandemic on the operations, clinical trials and financial condition of the Company. Company, unexpected safety or efficacy data. observed during preclinical studies or clinical trials, activation of clinical trial sites or recruitment rates below expectations, the potential product candidates that the Company is developing may not progress in clinical development or receive the regulatory approvals required on schedule or not at all, changes in or existing competition, changes in the regulatory environment, uncertainties and timing of the regulatory approval process, and litigation or other unforeseen disputes. Other factors that could cause the actual results of the Company to differ from those expressed or implied in the forward-looking statements in this current report on Form 8-K are identified in the section entitled “Risk Factors” in the Quarterly Report. of the company on form 10- Q for the quarter ended September 30, 2021 deposited with the Security and Trade Commission (“SEC”) and the Quebec

————————————————– ——————————

the Autorité des Marchés Financiers (“AMF”) on November 10, 2021, and its other documents subsequently filed or provided to the SECOND and the AMF. The Company expressly disclaims any obligation to update any forward-looking statements contained in this document, whether as a result of new information, future events, changed circumstances or otherwise, except as required by law otherwise.

Item 9.01 Financial Statements and Attachment.

(d) Exhibits

No.                                      Description

99.1          Press release dated January 7, 2022.

104         Cover Page Interactive Data File (embedded within the Inline XBRL

————————————————– ——————————

© Edgar online, source Previews

Comments are closed.